COMMUNIQUÉS West-GlobeNewswire

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
12/09/2025
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/ [...]
Global Pioneer: KFSHRC Showcases Robotic Organ Transplantation Leadership at C3 Davos of Healthcare™ New York Summit
11/09/2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has reinforced its position as a global pioneer in organ transplantation, marked by the world’s first fully [...]
Pennant Group to Participate in the 2025 Jefferies Healthcare Services Conference
11/09/2025
EAGLE, Idaho, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it [...]
Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum
11/09/2025
SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief [...]
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
11/09/2025
Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: [...]
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
11/09/2025
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for [...]
Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results
11/09/2025
KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter [...]
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
11/09/2025
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/09/2025
NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
11/09/2025
TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a pioneering biopharmaceutical company developing exosome- [...]
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
11/09/2025
Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs [...]
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
11/09/2025
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work ® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List . [...]
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
11/09/2025
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
InnovAge Named as One of the Nation’s Best Workplaces in Aging Services™ by Fortune® and Great Place to Work®
11/09/2025
A Leading Provider of PACE, Ranked in Top Tier of 2025 Best in Aging Services Category DENVER, Sept. 11, 2025 (GLOBE NEWSWIRE) -- InnovAge (NASDAQ: INNV), a leading provider of Program of All-Inclusive Care for the [...]
RESTEM to Host R&D Day Highlighting its Next-Generation Immunomodulatory Treatment for Autoimmune and Inflammatory Diseases
11/09/2025
Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), rheumatoid arthritis (RA), and facioscapulohumeral muscular dystrophy (FSHD) [...]
Faraday Pharmaceuticals to Participate in Upcoming Investor Events
11/09/2025
Topline data from pivotal Phase 3 Iocyte AMI-3 trial expected in Q4 2025 SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart [...]
Ipsen - Août 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
11/09/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
11/09/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites cellules
11/09/2025
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites [...]

Pages